Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
It promises fewer injections for vision loss patients
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
Rising demands and advancements in eye care drive growth
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
Subscribe To Our Newsletter & Stay Updated
